1-3 of 3
Keri Toner
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Real-world use of tisagenlecleucel in children and young adults with relapsed or refractory B-cell lymphomas

Clinical Trials & Observations
Jonathan D. Bender, Sudarshawn Damodharan, Christian M. Capitini, Amy Moskop, Keri Toner, Anant Vatsayan, Julie-An Talano, Christina Baggott, Deborah Schiff, Emmanuel Katsanis, Arunkumar J. Modi, Troy C. Quigg, Sunil S. Raikar, Liora M. Schultz, Lauren Pommert
Journal: Blood Advances
Blood Adv (2024) 8 (15): 4164–4168.
https://doi.org/10.1182/bloodadvances.2024012928
Published: 2024
Includes: Supplemental data
Journal Articles

Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children’s Oncology Group study

Clinical Trials & Observations
Birte Wistinghausen, Keri Toner, Donald A. Barkauskas, Lauren P Jerkins, Hannah Kinoshita, Pamela Chansky, Gloria Pezzella, Lauren Saguilig, Robert J. Hayashi, Harshal Abhyankar, Brooks Scull, Vivekanudeep Karri, Jay Tanna, Patrick Hanley, Michelle L. Hermiston, Carl E. Allen, Catherine M. Bollard
Journal: Blood Advances
Blood Adv (2024) 8 (5): 1116–1127.
https://doi.org/10.1182/bloodadvances.2023010832
Published: 2024
Includes: Supplemental data
Journal Articles

Tumor-associated antigen–specific T cells with nivolumab are safe and persist in vivo in relapsed/refractory Hodgkin lymphoma

Clinical Trials & Observations
Hema Dave, Madeline Terpilowski, Mimi Mai, Keri Toner, Melanie Grant, Maja Stanojevic, Christopher Lazarski, Abeer Shibli, Stephanie A. Bien, Philip Maglo, Fahmida Hoq, Reuven Schore, Martha Glenn, Boyu Hu, Patrick J. Hanley, Richard Ambinder, Catherine M. Bollard
Journal: Blood Advances
Blood Adv (2022) 6 (2): 473–485.
https://doi.org/10.1182/bloodadvances.2021005343
Published: 2022
Includes: Supplemental data